NCT04080505 is a Phase 3 clinical trial of SSKI- Potassium Iodide in Graves Disease, sponsored by Columbia University.

Who is sponsoring NCT04080505?

NCT04080505 is sponsored by Columbia University.

What drugs are being tested in NCT04080505?

Interventions in NCT04080505: SSKI- Potassium Iodide.

What condition does NCT04080505 study?

NCT04080505 studies Graves Disease.

Is NCT04080505 still recruiting?

NCT04080505 is currently terminated. Last updated 19 September 2024.

Are results published for NCT04080505?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-09-19 · How we verify

NCT04080505

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?

Terminated Phase 3 Results posted Last updated 19 September 2024

What this trial tests

Phase 3 trial testing SSKI- Potassium Iodide in Graves Disease in 29 participants. Terminated before completion.

Timeline

10 February 2015

Primary endpoint
3 March 2023

3 March 2023

Quick facts

Lead sponsor	Columbia University
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	29
Start date	10 February 2015
Primary completion	3 March 2023
Estimated completion	3 March 2023
Sites	1 location across United States

Drugs / interventions tested

SSKI- Potassium Iodide — full drug profile →

Conditions studied

Graves Disease — all drugs for Graves Disease →

Sponsor

Columbia University

Who can join

18 and older, any sex, with Graves Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to find out if SSKI (Potassium Iodide) reduces vascularity (the number and concentration of blood vessels) and improves how well patients do after surgery for removal of their whole thyroid gland in Graves' disease (an autoimmune disease that is a common cause of hyperthyroidism).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Graves Disease

Currently open trials in the same condition.

NCT07480720 — Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease · recruiting
NCT07305818 — NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease · Phase 1 · recruiting
NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
NCT07129642 — Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease · EARLY_PHASE1 · recruiting
NCT07369063 — Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease · Phase 2 · recruiting

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04080505 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04080505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing